124P Discordance between HRD status and clinical outcomes in advanced ovarian cancer: A real-world retrospective cohort of 80 patients

Homologous recombination deficiency (HRD) status is widely used to guide treatment decisions in advanced ovarian cancer, particularly in the context of PARP inhibitors. However, real-world evidence suggests that HRD classification may not fully capture the biological heterogeneity underlying treatment response. We aimed to evaluate the concordance between HRD status and clinical outcomes in a contemporary cohort.